

- Federal Claims No: 19–1639V
89. Denise Bengston, Wichita, Kansas, Court of Federal Claims No: 19–1643V
90. Shannon Cobb, Blue Springs, Missouri, Court of Federal Claims No: 19–1645V
91. Robert Labianco, Virginia Beach, Virginia, Court of Federal Claims No: 19–1646V
92. Tara Hunley, Madera, California, Court of Federal Claims No: 19–1647V
93. Jessica Sandner, Portland, Oregon, Court of Federal Claims No: 19–1648V
94. Teresa Buchanan, Chattanooga, Tennessee, Court of Federal Claims No: 19–1649V
95. Lisa C. Salzer, Salisbury, North Carolina, Court of Federal Claims No: 19–1650V
96. Robert R. Jodoin, Manchester, New Hampshire, Court of Federal Claims No: 19–1651V
97. Janice Byrd, Boston, Massachusetts, Court of Federal Claims No: 19–1655V
98. Janna Glassberg, Boston, Massachusetts, Court of Federal Claims No: 19–1656V
99. Charisse Guasto, Tomah, Wisconsin, Court of Federal Claims No: 19–1658V
100. Jordan Briggs, Richardson, Texas, Court of Federal Claims No: 19–1659V
101. Robert Mele, Washington, Pennsylvania, Court of Federal Claims No: 19–1660V
102. Kimberly Martin, Dallas, Texas, Court of Federal Claims No: 19–1661V
103. Richard Rebeles, Chicago, Illinois, Court of Federal Claims No: 19–1662V
104. Casey Wilson on behalf of C. W., Reno, Nevada, Court of Federal Claims No: 19–1663V
105. Kevin Carasiti, Wading River, New York, Court of Federal Claims No: 19–1664V
106. Jennifer Cortez, San Diego, California, Court of Federal Claims No: 19–1669V
107. Ashley Wirges, Washington, District of Columbia, Court of Federal Claims No: 19–1670V
108. Valerie K. Hester on behalf of The Estate of Marion Hester, Deceased, Durham, North Carolina, Court of Federal Claims No: 19–1671V
109. Susan Fitzgerald, Washington, District of Columbia, Court of Federal Claims No: 19–1673V
110. David Griswold, Mission Hills, California, Court of Federal Claims No: 19–1674V
111. George Girard Hammer, Jeffersontown, Kentucky, Court of Federal Claims No: 19–1675V
112. Gerald Lengkeek, Holland, Michigan, Court of Federal Claims No: 19–1678V
113. Traci Jones, Redlands, California, Court of Federal Claims No: 19–1680V
114. MaryGrace Fagen, Schererville, Indiana, Court of Federal Claims No: 19–1681V
115. Kim Reed, Winfield, Alabama, Court of Federal Claims No: 19–1682V
116. Hanna Reynolds, Davie, Florida, Court of Federal Claims No: 19–1683V
117. Frank Coluccio, Beverly Hills, California, Court of Federal Claims No: 19–1684V
118. Sharon Stephens, Victorville, California, Court of Federal Claims No: 19–1685V
119. Trevor Miller, Allentown, Pennsylvania, Court of Federal Claims No: 19–1686V
120. Lindsay Carlson, Modena, New York, Court of Federal Claims No: 19–1687V
121. Kristin Ivanovski, Hackensack, New

- Jersey, Court of Federal Claims No: 19–1690V
122. Emily Hirst, Gainesville, Georgia, Court of Federal Claims No: 19–1691V
123. Kristi Napier, New Albany, Indiana, Court of Federal Claims No: 19–1692V
124. Raven Tubbs, Dallas, Texas, Court of Federal Claims No: 19–1693V
125. Jennifer Kohlmeyer, Englewood, New Jersey, Court of Federal Claims No: 19–1694V
126. Kathy J. Stopar, Racine, Wisconsin, Court of Federal Claims No: 19–1695V
127. Nidal Zaidan, Dresher, Pennsylvania, Court of Federal Claims No: 19–1697V
128. Lindsay Ward, Dresher, Pennsylvania, Court of Federal Claims No: 19–1698V
129. Mir Hassan, Bloomingdale, Illinois, Court of Federal Claims No: 19–1699V

[FR Doc. 2019–25099 Filed 11–19–19; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HIV/AIDS Clinical Trials Networks Statistical and Data Management Centers (UM1 Clinical Trial Required).

Date: December 12–13, 2019.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Cambria Hotel Rockville, 1 Helen Heneghan Way, Rockville, MD 20850.

Contact Person: Cynthia Louise De La Fuente, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 240–669–2740, delafuentec@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 14, 2019.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–25116 Filed 11–19–19; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required).

Date: December 16, 2019.

Time: 9:00 a.m. to 11:00 a.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Kelly Lorraine Hudspeth, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC–9823 Rockville, MD 20852, 240–669–5067, kelly.hudspeth@nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Collaborative Cross Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21).

Date: January 8–9, 2020.

Time: 9:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Margaret Allison Morris Fears, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, maggie.morrisfears@nih.gov.